Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated to v3.4.2. Older notices including v3.4.1 and the government funding status notice were removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a general status notice about government funding and NIH operations, and updated the site software version to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary toggle and new metadata labels: 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. Removed the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check35 days agoChange DetectedKey sections including Interventions/Treatment, Outcome Measures, Eligibility Criteria, and Study Record Dates appear to be removed. This reduces visibility into the trial design, endpoints, and enrollment details.SummaryDifference17%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no clinical trial data or page content changes were made. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA dedicated Locations section has been added with Zhejiang listed as the site. The page revision is updated to v3.3.3, and the old Zhejiang Locations entry plus the HHS Vulnerability Disclosure link have been removed.SummaryDifference0.2%

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.